Kazia Therapeutics Ltd ADR
KZIAAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Sep 1, 2026 | BTIG | $40.00(+207%) | $13.04 | TheFly | |
| Aug 13, 2026 | Canaccord Genuity | John Newman | $29.00(+127%) | $12.79 | TheFly |
| Jul 1, 2026 | BTIG | Kambiz Yazdi | $34.00(+141%) | $14.08 | TheFly |
| Jun 11, 2026 | Lake Street | $32.00(+178%) | $11.50 | TheFly | |
| Apr 15, 2026 | Laidlaw | $25.00(+164%) | $9.46 | TheFly | |
| Dec 12, 2025 | H.C. Wainwright | $18.00(+38%) | $13.09 | TheFly | |
| Oct 2, 2025 | Maxim Group | $20.00(+192%) | $6.84 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| BTIG | maintain | Buy | Sep 10, 2026 |
| BTIG | maintain | Buy | Sep 1, 2026 |
| BTIG | maintain | Buy | Jul 15, 2026 |
| HC Wainwright & Co. | maintain | Buy | Jan 28, 2026 |
| HC Wainwright & Co. | maintain | Buy | Dec 12, 2025 |
| Maxim Group | maintain | Buy | Oct 2, 2025 |
| HC Wainwright & Co. | maintain | Buy | Jul 10, 2025 |
| Maxim Group | maintain | Buy | Jun 11, 2025 |
| HC Wainwright & Co. | maintain | Buy | Jul 12, 2024 |
| HC Wainwright & Co. | upgrade | Neutral →Buy | Apr 11, 2023 |
| HC Wainwright & Co. | downgrade | Buy →Neutral | Aug 2, 2022 |
| Maxim Group | downgrade | Buy →Hold | Aug 2, 2022 |
| Maxim Group | maintain | Buy | Oct 14, 2021 |
| HC Wainwright & Co. | maintain | Buy | Jan 5, 2021 |
Earnings History
Next report: Mar 2, 2027 · EPS est. $-0.07| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Sep 4, 2026 | $-0.33 | $-0.61 | $150.4K | $488.9K |
| Mar 16, 2026 | $-0.58 | $-0.01 | $180.6K | — |
| Nov 7, 2025 | $-0.43 | $-0.01 | $10.5K | $10.5K |
| Jun 10, 2025 | $-3.81 | $-10.76 | $13.8K | $11.1K |
| Feb 20, 2025 | $-20.80 | $-15.00 | $1.7M | $100.0K |
| Sep 16, 2024 | $-0.30 | $-3.00 | $100.0K | $100.0K |
| Nov 27, 2023 | $-10.03 | — | $664.00 | $60.0K |
| Feb 28, 2023 | $-31.45 | $-24.65 | — | $7.7K |
News
Recognition Highlights Kazia's Focus on Overcoming Treatment Resistance in Cancer SYDNEY, Nov. 5, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, has been named "Drug Discovery Company of the Year" in the 2026 BioTech Breakthrough Awards program, recognizing the Company's innovative appr…
Presentations to Explore Paxalisib's Differentiated Tumor and Immune Reprogramming Activity SYDNEY, Nov. 2, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced that two abstracts highlighting new preclinical and translational research on paxalisib's differentiated biological …
SYDNEY, Oct. 29, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced that John Friend, MD, Chief Executive Officer, and Jeffrey Kraws, Head of Corporate Strategy & Development, will participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference, being held November 9 to 11…
Clinical Milestone Expands Development of Paxalisib Beyond Oncology and Triggers $2 Million Payment to Kazia SYDNEY, Sept. 22, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced that Sovargen Co., Ltd.
Multicenter study to evaluate paxalisib plus gemcitabine for children and young adults with recurrent or progressive AT/RT, where no approved therapies currently exist SYDNEY, Sept. 9, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced that the first patient has been dosed i…
Kazia Therapeutics Limited (KZIA) Discusses Clinical and Corporate Updates With Focus on Paxalisib Programs in Breast and Colorectal Cancer Transcript
Paxalisib Monotherapy Significantly Reduced Tumor Burden in Pre-Clinical Model of MSS/pMMR Colorectal Cancer, With the Addition of Pembrolizumab Driving a Further Reduction Paxalisib Was Well Tolerated as Monotherapy and in Combination with Checkpoint Inhibition Kazia is Preparing to Advance Paxalisib Into a Phase 2 Clinical Study to Evaluate Paxalisib in Immunotherapy-Resistant MSS/pMMR Colorectal Cancer SYDNEY, Sept. 1, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncolog…
Preclinical Data Show Paxalisib Combined With Standard-of-Care Therapy Is Well Tolerated and Produces Statistically Significant Antitumor Activity Three-Arm Expansion of the Ongoing TNBC Trial Will Evaluate Paxalisib Plus Fulvestrant, With Palbociclib, Versus Standard-of-Care First Patient Expected By Year-End 2026 and Full Enrollment by End of 2027 SYDNEY, Sept. 1, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology compan…
Company to host a corporate update call Tuesday, September 1st at 8:00am ET SYDNEY, Aug. 31, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced the closing of its previously announced oversubscribed, tranched registered public offering (the "Offering") generating approximate…
Kazia's first 6 TNBC patients all achieved clinical benefits. These early results make paxalisib a much more promising asset going forward. Responses across visceral, skeletal, and CNS metastases make that early signal more compelling. But it's a relatively small and uncontrolled cohort. KZIA is working towards an expanded Phase 1b trial with 36 patients. That should give us a clearer picture about paxalisib's potential.
SYDNEY, Aug. 28, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced the pricing of its previously announced tranched registered public offering (the "Offering") of (i) 2,580,000 American Depositary Shares ("ADSs"), each representing five hundred (500) ordinary shares of the …
SYDNEY, Aug. 27, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced that it has commenced a tranched registered public offering (the "Offering") of (i) American Depositary Shares ("ADSs"), each representing five hundred (500) ordinary shares of the Company, no par value per …
Durable Complete Metabolic Response Ongoing Since November 2025 All Evaluable Patients Demonstrated Reductions in Metastasis-Associated CTC Clusters and Terminally Exhausted T cells, With Median Reductions of 83% and 51% Respectively No Treatment-Related Serious Adverse Events Observed SYDNEY, Aug. 27, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology,…
Kazia Therapeutics is rated Strong Buy, driven by best-in-class potential for paxalisib and a discounted valuation. Paxalisib has shown strong efficacy in triple-negative breast cancer, including a complete response in a heavily pretreated patient. KZIA's pipeline is validated by recent PI3K/AKT/mTOR pathway approvals and acquisitions.